Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 7/20 | 0.42 |
| ▸ | JAK3 | P52333 | 6/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | STAT5B | P51692 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171771 | 0.85 | MEN1 (0.42) | JAK2JAK3PLK4PAK4NTRK1 | |
| SCHEMBL4303875 | 0.81 | JAK2 (0.49) | ITKJAK2JAK3PLK4PAK4 | |
| SCHEMBL4179956 | 0.81 | JAK2 (0.43) | ITKJAK2JAK3PLK4PAK4 | |
| SCHEMBL4168663 | 0.79 | AURKB (0.43) | ITKJAK2JAK3PLK4PAK4 | |
| SCHEMBL4164963 | 0.78 | MEN1 (0.49) | ITKPLK4PAK4NTRK1AURKB | |
| SCHEMBL4173931 | 0.78 | MEN1 (0.43) | ITKJAK2JAK3PLK4PAK4 | |
| SCHEMBL4162005 | 0.77 | JAK2 (0.39) | ITKJAK2JAK3NTRK1CYP3A4 | |
| SCHEMBL3965067 | 0.76 | NTRK1 (0.47) | ITKJAK2JAK3PLK4PAK4 | |
| SCHEMBL4169624 | 0.76 | ITK (0.43) | ITKJAK2JAK3NTRK1IGF1R | |
| SCHEMBL4179012 | 0.76 | MEN1 (0.46) | ITKJAK2JAK3PLK4PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | claimed |
| WO-2009089042-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | ITK 951/4885JAK2 39/4885JAK3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.